kg), 10 mg (for ≥20 kg to <30 kg), and 15 mg (for ≥30 kg):


Investigator’s Global Assessment of skin lesion improvement to clear (0) or almost clear (1) skin was observed as early as Week 4, with 41-47% of patients achieving it by Week 161

A 75% improvement in the Eczema Area and Severity Index score was observed as early as Week 4, with 69-73% of patients achieving it by Week 161

Itch relief - defined as a score of ≥4 on the Peak Pruritus Numerical Rating Scale (PP-NRS) - was observed as early as Week 1, with 72% of children aged 2 to 6 and 59% of children aged 7 to 11 achieving it at Week 161

Similar or higher response rates were observed at Week 52 for all these clinical endpoints demonstrating sustained efficacy over a year1


These phase II findings are consistent with the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis.2,
=*=*=*=*=*=
当前为第4/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页